British Journal of Cancer is the official journal of the Cancer Research Campaign and developed from the annual reports of research funded by the Campaign. The journal reflects the mission of the Campaign by including research on the entire field of cancer, ranging from molecular and mechanistic studies, through cell biology, pathology, experimental therapeutics, epidemiology and accounts of clinical studies. In a time of increased subspecialization in science, the need for a top-rate journal with broad coverage is paramount; all the more so as best clinical practice means multidisciplinary care for individual cancer patients. BJC appeals to a broad audience, which is reflected in its consistently impressive impact factors. Its popularity has led to a doubling in size and a move to biweekly publication. In addition to full research papers, the journal publishes high quality reviews, correspondence, book reviews, a calendar of future meetings and conferences and, occasionally, conference supplements. The journal has made provision for 'fast track' articles, which reduces considerably the normal publication time for communications deemed by the Editors and reviewers to be appropriate. The journal has a very large international database of expert reviewers and this guarantees high standards of peer review for all submitted articles. Normally a minimum of three reviewers are employed for each research manuscript submitted to the journal.

英國癌癥雜志是癌癥研究運(yùn)動的官方雜志，由該運(yùn)動資助的年度研究報(bào)告發(fā)展而成。該雜志反映了這一運(yùn)動的使命，包括對整個癌癥領(lǐng)域的研究，從分子和機(jī)械研究，到細(xì)胞生物學(xué)、病理學(xué)、實(shí)驗(yàn)治療學(xué)、流行病學(xué)和臨床研究報(bào)告。在科學(xué)亞專業(yè)化程度不斷提高的時代，對一本覆蓋范圍廣泛的一流期刊的需求至關(guān)重要；更重要的是，最佳臨床實(shí)踐意味著對單個癌癥患者進(jìn)行多學(xué)科護(hù)理。北京辛普勞吸引了廣大觀眾，這反映在其一貫令人印象深刻的影響因素。它的受歡迎程度使其規(guī)模翻了一番，并向每兩周出版一次的方向發(fā)展。除了完整的研究論文外，該雜志還出版高質(zhì)量的評論、信件、書評、未來會議和會議的日程表，偶爾還出版會議補(bǔ)充資料。《華爾街日報(bào)》已經(jīng)為“快速通道”的文章做了規(guī)定，這大大減少了編輯和審稿人認(rèn)為適當(dāng)?shù)臏贤ǖ恼３霭鏁r間。《華爾街日報(bào)》擁有一個非常龐大的專家評審員國際數(shù)據(jù)庫，這保證了所有提交文章的同行評審的高標(biāo)準(zhǔn)。通常情況下，提交給期刊的每一份研究稿至少要有三名審稿人。